Pharmaceutical companies play a crucial role in transforming R/R AML care. IMPACT-AML provides a platform to test innovative therapies, leverage real-world data, and collaborate with top researchers to drive breakthrough treatments and expand patient access.
The IMPACT-AML consortium invites Pharmaceutical Leaders to collaborate in advancing therapies for R/R AML. With STREAM we offer a platform to test innovative treatments in real-world and clinical settings, contributing to a transformative landscape for AML care. Together, we can address unmet needs and deliver life-changing solutions.
By collaborating with the IMPACT-AML Consortium, haematologists could gain access to state-of-the-art clinical trials, real-world data from STREAM, and a robust platform for joint research. This is your chance to contribute to transformative therapies, setting a new standard for AML care across Europe.
Leverage STREAM for real-world data collection and patient recruitment.
Navigate compliance with GDPR and clinical trial regulations with our expert guidance.
Validate therapies in diverse populations, enhancing external validity.
Collaborate with Europe’s top researchers and clinical sites.
Shape the future of R/R AML treatment, expanding market access and societal benefit.